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Recent measles epidemics in US and European cities where vaccination coverage has declined are
providing a harsh reminder for the need to maintain protective levels of immunity across the entire
population. Vaccine uptake rates have been declining in large part because of public misinformation
regarding a possible association between measles vaccination and autism for which there is no sci-
entiﬁc basis. The purpose of this article is to address a new misinformed antivaccination argu-
mentdthat measles immunity is undesirable because measles virus is protective against cancer.
Having worked for many years to develop engineered measles viruses as anticancer therapies, we have
concluded (1) that measles is not protective against cancer and (2) that its potential utility as a cancer
therapy will be enhanced, not diminished, by prior vaccination.
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the end of this article.THE QUESTION THAT PROMPTED THIS
REVIEW
Recently, one of us received an email mes-
sage from an exasperated teacher with the
subject line “please, please make a statement
about MMR (measles, mumps, rubella) vac-
cine.” The message read as follows:Mayo Clin Proc. n XXX 2019;nn(n):1-6 n https://doi.org/10.1016/j.m
www.mayoclinicproceedings.org n ª 2019 Mayo Foundation for Me
under the CC BY-NC-ND license (http://creativecommons.org/licens“I’m a teacher and your supportive
opinion would go a lot further than all the
numbers I can throw at parents. They see
your work and make some judgement about
measles being protective against cancer,
therefore do not vaccinate their kids. Please
answer. Do you advise families [to] immu-
nize their children on schedule?”THE ANSWER
The answer is an unequivocal YES, we do very
strongly advise families to immunize their
children on schedule. Measles is a serious
infection capable of killing infected children.
It caused 110,000 deaths worldwide in
2017.1,2 Vaccination protects against measles
and has been administered to over a billion
people with an exceptional safety record.
There is no evidence that measles infectionayocp.2019.05.006




2can protect against cancer. Our studies using
engineered measles viruses to treat cancer
have found the best outcomes in people who
have been vaccinated, and our current
approaches are fully geared to this group of
patients with cancer.
We are dismayed to learn that our work is
being cited in opposition to MMR (measles,
mumps, and rubella) vaccination and are
therefore taking this opportunity to review
the key pertinent facts about measles, measles
vaccination, and measles as an experimental
cancer therapy that support this position.THE FACTS ABOUT MEASLES
Measles spreads in respiratory droplets and
is the most transmissible virus known
(“coughs and sneezes spread diseases”).3,4
The R0 (numbers of people in a susceptible
population that will be infected by a single
person with measles) is 15 to 20, much
higher than the R0 of Ebola (1.5-2.5) or
inﬂuenza (1.4-4).5,6 After an incubation
period of 9 to 11 days, the virus causes a se-
vere head cold (conjunctivitis, swollen eye-
lids, photophobia, hacking cough, and
nasal discharge) with associated fever, irrita-
bility, and general malaise that lasts 3 to 4
days, then gives way to a blotchy maculo-
papular rash that starts on the forehead,
spreads down over the face, neck, and trunk
to the feet, and lasts around 6 days.
Most children infected with the virus
recover completely and develop lifelong im-
munity to reinfection. However, recovery is
not guaranteed, and the infection can lead
to several serious complications that are
collectively responsible for the high mortal-
ity and long-term morbidity of measles.7,8
If the virus spreads more extensively in
the body, it can cause bronchitis, bronchioli-
tis, viral pneumonia, corneal ulceration and
blindness,myocarditis, hepatitis, and enceph-
alomyelitis. Also, and not widely appreciated,
measles in pregnancy can result in devas-
tating loss. In one study of 58 pregnant
women with active measles infection, 15
women experienced pneumonia, 13 had pre-
mature deliveries, and 5 had spontaneous
abortions.9,10Mayo Clin Proc. n XXXAside from causing damage to infected
tissues, measles is powerfully immunosup-
pressive due to direct lymphocyte infec-
tion/killing as well as inhibiting the
proliferation of uninfected lympho-
cytes.4,11,12 Secondary bacterial pneumonia
and bacterial otitis media are therefore
frequently encountered during measles.
Immunosuppression may persist for weeks
after measles resolution, as evidenced by
impairment of the delayed type hypersensi-
tivity reaction to intradermal tuberculin,
and patients are therefore at substantially
increased risk for tuberculosis reactivation
and other opportunistic infections during
this time.13 One to three in 1000 children
contracting measles will have development
of encephalitis concurrent with measles
infection,14 of whom 10% to 15% will die
and a further 25% will have long-term
neurologic damage.15 Additional postinfec-
tious complications include a progressive
fatal encephalitis with onset 1 to 6 months
postinfection in 1 in 1000 children15
compared with 1 to 2 in 1 million following
live virus vaccination,16 and 1 in 25,000
children with measles will have develop-
ment of subacute sclerosing panencephalitis
with typical onset many years later.14 In the
United States, this ﬁgure has been reported
to be as high as 1 in 1367 for children
younger than 5 years old.17
Because of differences in the availability
of supportive care and risk of exposure to
serious opportunistic pathogens, overall
measles mortality varies country to country
from 0.1% to 3.0%. In 2017, 110,000 people
died from measles, mostly children under
age 5 years.1 However, even the lower of
these mortality numbers is frightening
when caring for an infected infant and fully
justiﬁes the international effort to eradicate
the disease.
Before the availability of measles vaccina-
tion, epidemics in large population centers
occurred every 2 to 3 years, and 95% of chil-
dren were immune by age 15 years. New
epidemics therefore almost entirely impacted
younger children. This was fortunate
because measles in adults is more severe
than measles in children.2019;nn(n):1-6 n https://doi.org/10.1016/j.mayocp.2019.05.006
www.mayoclinicproceedings.org
MEASLES VACCINATIONTHE FACTS ABOUT MEASLES VACCINATION
The goal of vaccination is to induce protective
levels of circulating antimeasles antibodies.
This is achieved through subcutaneous injec-
tion of a small dose of a replication-competent
strain of measles virus attenuated and
rendered nonpathogenic by years of tissue
culture passage and adaptation on a variety
of cell substrates.5
The strain of measles virus most widely
used for vaccination was originally isolated
from the throat of an 11-year-old boy named
David Edmonston in 1954.18,19 In the nearly
70 years since Edmonston (Edm)elineage
viruses were ﬁrst used for vaccination, there
has never emerged a wild-type measles virus
that can evade the neutralizing anti-Edm
antibody response. Early Edm vaccines
were less stringently attenuated than those
currently in use and were prone to causing
a mild measleslike illness (reactogenic).
Newer vaccine strains are extremely well
tolerated, causing only minimal and short-
lived adverse effects in vaccines.6
Given that autism is often ﬁrst mani-
fested around the time of measles vaccina-
tion, reports of autism arising shortly after
the ﬁrst exposure to a measles vaccine are
inevitable. However, detailed statistical anal-
ysis of the temporal relationships of vaccina-
tion to autism onset provides no support for
a causal connection, nor is there a plausible
mechanistic basis to even suspect a connec-
tion.20-23
The best way to protect a population from
measles virus is to maintain immunity levels
greater than 95% by vaccinating as many chil-
dren as possible as soon as they are old
enough to respond to the vaccine.24,25 If vac-
cine coverage drops below a critical threshold
level, the number of susceptible children in a
population can rapidly increase to the point at
which a measles epidemic can easily be sus-
tained, whereupon most of those individuals
not vaccinated will likely succumb to measles
infection and population immunity will
temporarily be restored to protective levels.
In the face of an advancing epidemic,
nonimmune individuals can be speedily pro-
tected, either by administering pooledMayo Clin Proc. n XXX 2019;nn(n):1-6 n https://doi.org/10.1016/j.m
www.mayoclinicproceedings.orghuman gamma globulin within 6 days of vi-
rus exposure or by vaccination any time
before or up to 3 days after virus exposure.26
However, the logistics of “last-minute” vacci-
nation during a rapidly spreading epidemic
are problematic.
With high enough global vaccine
coverage, it should in theory be possible to
eradicate measles, and the World Health Or-
ganization is aggressively pursuing this
goal.5 However, there are signiﬁcant barriers
to achieving the levels of vaccine coverage
required for global eradication that will need
to be addressed if this dream is ever to be
realized.
The ﬁrst major barrier has to do with the
timing of measles vaccination. Newborns are
generally protected frommeasles by antibodies
that they acquire from theirmothers in utero.27
Unfortunately, in addition to being resistant to
measles infection, the babies of measles-
immune mothers are also resistant to measles
vaccination because their transplacentally ac-
quired antibodies neutralize the vaccine. For
this reason, vaccination is not initiated until
12 to 15 months of age in countries with low
measles incidence vs 9 to 12 months of age in
countries with higher incidence.28
These timelines create a “window of
vulnerability” for children younger than 9
to 12 months once they have lost the protec-
tion of their maternally acquired antibodies,
which disappear from the bloodstream with
a half-life of only 1 month. For this reason,
one of the major goals of measles vaccine
research is to develop a vaccine that will be
effective even in the presence of maternally
acquired antimeasles antibodies and that
can therefore be effectively administered at
a younger age.27,29,30 In this regard, we
have recently engineered the surface pro-
teins of the Edm vaccine strain to create a
derivative virus that is not only effective in
the presence of antibodies from vaccinated
mothers but also retains the ability to stimu-
late the production of antibodies capable of
neutralizing wild-type measles viruses.31
The second major barrier to measles eradi-
cation is simply getting people to vaccinate
their children. This can be particularly difﬁcultayocp.2019.05.006 3
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4in areas of conﬂict (eg, war zones) where the
cost and logistics of supplying the vaccine can
be highly problematic.32 Perhaps even more
challenging than war zone logistics, however,
is the recent epidemic of unfounded and irra-
tional anxieties regarding vaccine-induced
autism, which is driving an ever-increasing
number of parents to refuse permission for
their infants to be vaccinated.33,34
And now, adding insult to injury, the
additional argument of measles infection be-
ing “good for cancer” appears to be gaining
traction.
THE FACTS ABOUT MEASLES
VIROTHERAPY
Experiments of nature, such as the sponta-
neous regression of a large retro-orbital Bur-
kitt lymphoma coincident with measles,
point to the possibility of using measles as
an anticancer drug.35 However, it is impor-
tant to emphasize there is no evidence to
suggest that natural measles infection can
protect against the later development of
cancer.
Regarding the development of measles as
an anticancer drug, the naturally occurring
(wild-type) virus is a dangerous pathogen,
not suitable for use as a cancer therapy.
We and others therefore decided to deter-
mine whether attenuated measles strains
belonging to the Edm vaccine lineage had
anticancer potential, and the result of these
endeavors is now an extensive literature doc-
umenting that this is indeed the case.36,37
Attenuated Edm-lineage measles viruses
are selectively destructive to cultured human
cancer cells of many different tissue origins
and to human tumor xenografts grown in
immunodeﬁcient mice.38 Various “therapeu-
tic” genes have been added to the measles
genome to further enhance its “druggability”
and to increase its potency as an anticancer
therapy. Moreover, technologies have been
developed that allow the exquisite targeting
of measles virus tropism so that it can now
be engineered for highly speciﬁc infection
and killing of only unwanted cancer cells.39,40
At least 3 different measles virus constructs
have been administered to date to more thanMayo Clin Proc. n XXX150 patients with cancer in clinical trials,
and the results from those studies have been
highly encouraging.36,37,41-44
In one study at Mayo Clinic, a 49-year-old
woman with multiple myeloma that had
become refractory to all available therapies
(including 2 stem cell transplants) had a
remarkable response to a single intravenous
infusion of measles virus.36 After a short-
lived febrile reaction to the virus infusion,
all 5 of her rapidly growing plasma cell tumors
resolved completely and her bone marrow
was completely free of myelomatous plasma
cells. She did have a focal disease recurrence
9 months after measles virus infusion and
again at 2 years posttreatment, but both of
these relapses responded briskly to local radi-
ation therapy and her disease remains in com-
plete remission today, 51/2 years later, with no
additional myeloma drug therapy.
Although several additional patients with
cancer have responded favorably to single-
agent measles virus therapy since that time,
we have not yet seen a comparable durable
complete remission. Careful analysis of the
extensive correlative data sets amassed on
this best-responding patient revealed that
her tumor carried a very high mutational
burden, she had a high baseline frequency
of measles-reactive and tumor-reactive T
cells, and, despite a history of recent measles
vaccination (after her ﬁrst stem cell trans-
plant), she had virtually undetectable circu-
lating antimeasles antibodies (S.J.R., N.P.,
unpublished data, 2019).
All of these parameters are now believed to
have acted in concert to shape the favorable
response to measles therapy in this patient.
The absence of antimeasles antibodies allowed
the virus to access sites of tumor growth via the
bloodstream and to mediate inﬂammatory
killing of myeloma cells in situ. The abundant
antimeasles T cells were rapidly recruited to
infected tumors where they further boosted
the killing of measles-infected cells, thereby
accelerating the recruitment of a second wave
of T cells speciﬁcally recognizing a range of
myeloma-speciﬁc tumor antigens and there-
fore capable of killing residual uninfected
myeloma tumor cells.2019;nn(n):1-6 n https://doi.org/10.1016/j.mayocp.2019.05.006
www.mayoclinicproceedings.org
MEASLES VACCINATIONThus, our current perspective is that the
optimal scenario for effectivemeasles virother-
apy is that the patient should, at the time of
treatment, have abundant antimeasles T cells
but no antimeasles antibodies. Provided the
patient has previously received the measles
vaccine, this ideal scenario can be achieved in
the following ways: (1) by transiently
depleting antimeasles antibodies pretherapy,
(2) by using measles-infected cell carriers to
deliver the virus, thereby evading antimeasles
antibodies,45,46 and (3) by engineering an
oncolyticmeasles virus that is no longer recog-
nized by antimeasles antibodies.47,48
All 3 of these scenarios are actively pur-
sued at Mayo Clinic. Most advanced is the
cell carrier strategy, which is being evaluated
in patients with ovarian cancer using fat-
derived autologous mesenchymal stem cells
that are infected with measles virus and
administered immediately into the perito-
neal cavity45,46 (ClinicalTrials.gov Identiﬁer:
NCT02068794). In addition to this
approach, a third-generation oncolytic mea-
sles virus, resistant to antimeasles anti-
bodies, will shortly be advanced into the
translational pipeline (S.J.R., M.M.-A., un-
published data, 2019).CONCLUSION
Measles is a very serious, highly transmis-
sible, and potentially deadly viral infection
that despite intensive efforts to achieve global
vaccination coverage was still responsible for
over 100,000 deaths in 2017. Recent epi-
demics in US and European cities where
vaccination coverage is low provide a harsh
reminder for the need to maintain protective
levels of immunity across the entire popula-
tion. Newer vaccines are being developed so
that infants can be vaccinated before they
lose the protection afforded by antibodies ac-
quired transplacentally. Measles virotherapy
should not be used as an argument in opposi-
tion to measles vaccination because the most
promising approaches currently being devel-
oped are designed to give superior outcomes
in vaccinated vs unvaccinated individuals.Mayo Clin Proc. n XXX 2019;nn(n):1-6 n https://doi.org/10.1016/j.m
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